TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02134912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT05502276

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Full-Thickness Resection (EFTR)
Description: Full Thickness Endoscopic Resection using the FTRD Ovesco Device
Study: NCT02191605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSBIRT
Description: A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored texting
Description: Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored texting
Description: Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
Study: NCT04759469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: High-intensity interval training is a form of intermittent training using relatively high exercise intensity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity interval training
Description: Moderate intensity interval training is a form of intermittent training using moderate exercise intensity
Study: NCT02174653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPs® 7630
Description: 20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPs® 7630
Description: 20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
Study: NCT04204356

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Language treatment for improving discourse production
Description: All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language treatment for improving discourse production
Description: All participants will receive a 6-week block of language treatment for improving verb retrieval in discourse production by a professional speech and language therapist. The treatment goals for this block of treatment are to 1) improve verb retrieval and language quantity and complexity in discourse production 2) improve functional communication skills and; 3) improve quality of life and psychological state in people with post-stroke chronic aphasia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct-current stimulation (tDCS)
Description: Transcranial direct-current stimulation is a non-invasive brain stimulation method that can modify spontaneous cortical activity in targeted brain regions. Anodal tDCS delivered through a positively charged electrode has been found to increase cortical excitability in a targeted brain region. The use of tDCS as an adjunct to speech and language therapy has been found to improve aphasia treatment effects in post stroke patient populations.
Study: NCT03874390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ozone
Description: gaseous ozone was applied on periodontal pocket two times in one week.
Study: NCT00003573

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04091373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the upper arm

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the upper arm
Study: NCT05502276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Submucosal Dissection (ESD)
Description: Standard Endoscopic Submucosal Dissection using standard procedure described in international guidelines.
Study: NCT03874390

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: gaseous ozone was applied on periodontal pocket two times in one week.
Study: NCT04555876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone external muscle stimulation- stationary bicycle
Description: high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone external muscle stimulation- stationary bicycle
Description: high-tone external muscle stimulation (HTEMS), with Frequencies continuously will be scanned from 4096 Hz to 31768 Hz, allowing for a much higher power of up to 5000 mW to be introduced 3 times per week, for 10 weeks
Study: NCT03550040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Description: Surgical removal of the prostate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: Surgical removal of the prostate
Study: NCT01005875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Nexavar in bottles of 120 tables

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: SBRT
Study: NCT03312075

Intervention type: OTHER
Intervention: Sputum and blood samples
Description: The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
Study: NCT00195702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Study: NCT00195702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
Study: NCT00309192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal Injection 4mg single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Grid laser
Description: Grid laser as specified in ETDRS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Grid laser
Description: Grid laser as specified in ETDRS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Simulation procedure for triamcinolone injection
Study: NCT02095028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention
Description: participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
Study: NCT02683330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Description: MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
Study: NCT04091373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the upper arm

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the upper arm

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen
Study: NCT02416466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CEA CAR-T cells
Description: Gene modified patient T cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sir-Spheres
Description: SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
Study: NCT02698917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaCO2
Description: 4.5-4.7 kPa
Study: NCT04091373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the lower abdomen

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh
Study: NCT02517632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise, nutritional and pharmaceutical counceling
Description: The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional and pharmaceutical counceling
Description: The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
Study: NCT01159600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI 10773 high dose
Description: Placebo tablets matching BI 10773 high dose
Study: NCT04091373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh
Study: NCT02698917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaCO2
Description: 4.5-4.7 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaCO2
Description: 4.5-4.7 kPa
Study: NCT02920723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Study: NCT04091373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: cotadutide multidose pen injection
Description: SC injection in the thigh
Study: NCT02698917

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaCO2
Description: 5.8-6.0 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaCO2
Description: 5.8-6.0 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaCO2
Description: 5.8-6.0 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaCO2
Description: 5.8-6.0 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2
Description: 10-15 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2
Description: 10-15 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2
Description: 10-15 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal PaO2
Description: 10-15 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: 20-25 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: 20-25 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: 20-25 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal PaO2
Description: 20-25 kPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: 65-75 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: 65-75 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: 65-75 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low normal MAP
Description: 65-75 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: 80-100 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: 80-100 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: 80-100 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High normal MAP
Description: 80-100 mmHg
Study: NCT03961529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% OPA-15406 ointment
Description: Twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% OPA-15406 ointment
Description: Twice daily
Study: NCT03830463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-692
Description: Single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study: NCT01159600

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI 10773 low dose
Description: Placebo tablets matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily high dose open label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo identical to BI 10773 low dose
Description: Placebo tablets matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo identical to BI 10773 high dose
Description: Placebo tablets matching BI 10773 high dose
Study: NCT00963924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
Study: NCT03695510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Oral Tablet
Description: 40mg oral, daily, continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection
Description: 200mg, intra-venous injection, every 3 weeks, for 35 cycles
Study: NCT01154621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
Study: NCT02920723

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study: NCT02965885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-116
Description: TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
Study: NCT01154621

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 5% dextrose solution
Study: NCT03371628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
Study: NCT02994160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast electrode
Description: Implant temporary Fast electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
Study: NCT00625859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
Study: NCT04542863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-DX600 PET/CT
Description: DX600, labeled with 18F will be used as a molecular imaging tracer for PET/CT scanning
Study: NCT03759444

Intervention type: OTHER
Intervention: Questionnaires
Description: The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.

Intervention type: OTHER
Intervention: Questionnaires
Description: The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
Study: NCT04098172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Guidewire
Description: Fractional Flow Reserve measurement
Study: NCT05563441

Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: Patients over 70 years old underwent laparoscopic or laparotomic colorectal resection were enrolled.
Study: NCT03198585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Capsule, once a day for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, once a day for 90 days
Study: NCT02113891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant).
Study: NCT01939067

Intervention type: DEVICE
Group type: OTHER
Intervention: Heated Humidified High Flow Nasal Cannula
Description: Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.

Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Continuous Positive Airway Pressure
Description: Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
Study: NCT04225104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yogic breathing intervention
Description: Yogic breathing will be completed while following a video provided by the investigative team. Breathing practices consist of slow, deep, relaxation breathing and are led by a certified yoga instructor.